News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
169 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39672)
2015 (44432)
2016 (38329)
2017 (37188)
2018 (39119)
2019 (51334)
2020 (57663)
2021 (58720)
2022 (53927)
2023 (42564)
2024 (37441)
2025 (33090)
2026 (21902)
Month
January (3218)
February (3391)
March (3462)
April (3660)
May (4506)
June (2887)
July (2191)
August (2499)
September (2720)
October (3233)
November (3383)
December (2291)
Day
1 (102)
4 (174)
5 (247)
6 (211)
7 (265)
8 (238)
11 (138)
12 (205)
13 (219)
14 (240)
15 (174)
18 (169)
19 (181)
20 (151)
21 (144)
22 (81)
23 (1)
25 (165)
26 (154)
27 (94)
28 (19)
29 (11)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
4
5
6
7
8
11
12
13
14
15
18
19
20
21
22
23
25
26
27
28
29
Press Releases
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
November 18, 2024
·
17 min read
Press Releases
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
November 18, 2024
·
14 min read
Editorial
AbbVie’s Setback Gives BMS Commanding Lead in Schizophrenia Space
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is ‘sole muscarinic winner.’
November 18, 2024
·
5 min read
·
Heather McKenzie
Press Releases
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering
November 18, 2024
·
6 min read
Press Releases
FDA Roundup: November 15, 2024
November 18, 2024
·
3 min read
Press Releases
Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements
November 18, 2024
·
3 min read
Press Releases
Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock
November 18, 2024
·
4 min read
Press Releases
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
November 18, 2024
·
12 min read
Press Releases
SHORELINE BIOSCIENCES TO PRESENT AT 2024 STIFEL HEALTHCARE CONFERENCE
November 18, 2024
·
1 min read
Press Releases
Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
November 18, 2024
·
4 min read
Previous
2 of 17
Next
